Association of negatively-charged phospholipids with low-density lipoprotein (LDL) increases its uptake and the deposition of cholesteryl esters by macrophages.
LDL, the major carrier of cholesterol in blood, is poorly metabolized by macrophages. In contrast, macrophages can recognize and endocytose anionic phospholipids such as phosphatidylserine, phosphatidylglycerol and cardiolipin. Since macrophages can take up large amounts of these phospholipids, experiments were performed to ascertain whether pre-incubation of native LDL with negatively-charged phospholipids would enhance the metabolism of LDL by macrophages. When 125I-LDL was incubated with cardiolipin liposomes for 18 h at 37 degrees C before addition to macrophages, an approx. 40-fold increase of LDL metabolism by these cells was observed. Similar results were found when LDL was pre-incubated with phosphatidylserine or phosphatidylglycerol; however, pre-incubation of LDL with phosphatidylcholine liposomes did not lead to an increase of LDL metabolism. The macrophage uptake of LDL pre-incubated with cardiolipin was reduced to approx. 40% of control values in the presence of dextran sulfate and fucoidin, inhibitors of anionic phospholipid uptake. Cytochalasin D, an inhibitor of phagocytosis, reduced the lysosomal degradation of LDL pre-incubated with cardiolipin to approx. 10% of control values. When the LDL-cardiolipin mixture was chromatographed on agarose gel, two peaks containing LDL were observed in the elution profile: the first peak appeared at the void volume and the second peak was detected just ahead of native LDL. The LDL in both peaks was much more extensively metabolized by macrophages than was native LDL; the LDL in the first peak was metabolized at a rate that was 8 times the second peak. The results demonstrate that negatively-charged phospholipids can form a complex with LDL which facilitates its phagocytosis by macrophages.
Greenspan
P
P
University of Georgia, College of Pharmacy, Department of Pharmacology and Toxicology, Athens 30602, USA.
Ryu
B H
BH
Mao
F
F
Gutman
R L
RL
D002308:Cardiolipins / Q000378:metabolism; D002460:Cell Line; D002738:Chloroquine / Q000494:pharmacology; D002788:Cholesterol Esters / Q000378:metabolism*; D015638:Cytochalasin D / Q000494:pharmacology; D016264:Dextran Sulfate / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D008077:Lipoproteins, LDL / Q000378:metabolism*; D008081:Liposomes; D008247:Lysosomes / Q000378:metabolism; D008264:Macrophages / Q000378:metabolism*; D010587:Phagocytosis; D010715:Phosphatidylglycerols / Q000378:metabolism; D010718:Phosphatidylserines / Q000378:metabolism; D010743:Phospholipids / Q000737:chemistry / Q000378:metabolism*; D013433:Sulfoglycosphingolipids / Q000494:pharmacology
D002308:Cardiolipins; D002788:Cholesterol Esters; D008077:Lipoproteins, LDL; D008081:Liposomes; D010715:Phosphatidylglycerols; D010718:Phosphatidylserines; D010743:Phospholipids; D013433:Sulfoglycosphingolipids; D015638:Cytochalasin D; D002738:Chloroquine; D016264:Dextran Sulfate